奈达铂腔内灌注治疗恶性胸腔积液的临床疗效  

Efficacy of intracavitary instillation of nedaplatin in treating malignant hydrothorax

作　　者：李英[1] 童金龙[1] 何耿劲[1] 

机构地区：[1]南京市第二医院肿瘤科,江苏省210003

出　　处：《江苏医药》2015年第23期2823-2825,共3页Jiangsu Medical Journal

摘　　要：目的观察胸腔内注射奈达铂治疗恶性胸腔积液的临床疗效及不良反应。方法 62例恶性胸腔积液患者随机分为治疗组(32例)和对照组(30例),经B超定位胸腔置管引流。排净积液后,治疗组胸腔内注入奈达铂,对照组胸腔内注入顺铂。结果治疗组完全缓解8例,部分缓解17例,对照组分别为5例和11例。治疗组有效率高于对照组(78.1%vs.53.3%)(P<0.05)。治疗组胃肠道反应发生率为15.6%,低于对照组的46.7%(P<0.05)。结论奈达铂腔内灌注治疗恶性胸腔积液的疗效优于顺铂,不良反应小。Objective To observe the clinical efficacy and adverse effects of intracavitary instillation of nedaplatin in the treatment of malignant hydrothorax .Methods Localized by B‐ultrasonic , the catheter was inserted into thorax for the drainage of hydrothorax in 62 patients with malignant hydrothorax .After emptying effusion ,the patients were randomly assigned into two groups and infused intrathoracically with nedaplatin（group A ,32 cases） or cisplatin（group B ,30 cases） .Results The numbers of patients with complete remission and partial remission after treatment were 8 cases and 17 cases in group A ,which were 5 cases and 11 cases in group B .The effectiveness rate of treatment was significantly higher in group A than that in group B（78.1% vs .53.3% ）（P〈0 .05） . The incidence rate of gastrointestinal adverse effects was lower in group A than that in group B （15.6% vs .46.7% ） （ P〈0 .05 ） .Conclusion Nedaplatin by intracavity instillation is better than cisplatin in the treatment of malignant hydrothorax with less gastrointestinal adverse effects .

关 键 词：奈达铂 顺铂 恶性胸腔积液 

分 类 号：R730[医药卫生—肿瘤]